Navigation Links
Michael J. Fox Foundation Announces $2 Million Funding Commitment to Drive Development of Parkinson's Disease Biomarker Pipeline
Date:5/7/2009

Initiative is one element of broader strategy to speed biomarkers progress

NEW YORK, May 7 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research announced a funding commitment of $2 million for Biomarkers 2009. This fourth round of biomarker funding by MJFF aims to continue stimulating discovery of new disease and drug biomarkers. At the same time, recognizing the critical need for an orchestrated, fieldwide strategy to drive tangible progress, MJFF is putting building blocks in place to launch a comprehensive biomarker discovery and verification effort in coming months.

"Lack of biomarkers is a major impediment to the development of disease-modifying treatments for Parkinson's disease, in large part because outcomes of clinical trials are extremely difficult to measure," said Katie Hood, CEO. "While considered a high-risk pursuit by many, The Michael J. Fox Foundation will continue to push biomarker research because development of PD biomarkers would be a major tipping point for the field, greatly accelerating the development of transformative new therapies."

The Foundation has been a field leader in the development of PD biomarkers for several years. Approximately $9 million in MJFF investment to date has resulted in the emergence of several lead biomarker candidates. Today's additional $2 million, directed toward biomarker discovery, underscores that commitment. Biomarkers 2009 will prioritize continued development of two separate types of biomarkers, both of major importance to PD therapeutics development: disease biomarkers and drug biomarkers.

Disease biomarkers are distinctive biological features or changes that are consistently different in people with PD than in people without PD. Identifying one or more disease biomarkers would allow researchers to diagnose earlier, track disease progression and identify appropriate subjects for clinical trials. Drug biomarkers are critical for objectively assessing whether a given drug is reaching brain areas of interest and/or achieving a desired effect.

Abbreviated information for applicants is below. Full details are available at www.michaeljfox.org/research.cfm.

Biomarkers 2009

Total available funding: $2 million

Deadline: 6 p.m. ET, Thursday, August 13, 2009

Funding Anticipated: November/December 2009

The Michael J. Fox Foundation is dedicated to ensuring the development of better treatments, and ultimately a cure, for Parkinson's disease through an aggressively funded research agenda. MJFF has funded over $142 million in research to date.

    Media Contact:
    Holly Barkhymer
    (212) 509-0995 x242
    hbarkhymer@michaeljfox.org

    Research Contact:
    Mark Frasier, PhD
    (212) 509-0995 x244
    mfrasier@michaeljfox.org


'/>"/>
SOURCE Michael J. Fox Foundation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Celebrated Architect Michael Graves to Keynote HEALTHCARE DESIGN.09 Conference
2. Aleres Dr. Michael Taitel Provides Insights Into Reducing Health and Productivity Costs During Turbulent Economic Times
3. Dr. Michael B. Cates Takes Leadership Role on AVMAs One Health Joint Steering Committee
4. NeuroFocus Appoints Dr. Michael Smith as Partner in Consulting Practice
5. Sigma-Aldrich Announces Appointment of Michael Kanan as Vice President and Corporate Controller
6. J. Michael Cook to Retire from Lilly Board of Directors
7. Michael J. Kussman, VA Under Secretary for Health, to Retire
8. Foundation for Biomedical Research Announces Michael E. DeBakey Journalism Awards
9. Michael DeMane Joins Thomas, McNerney & Partners as Senior Advisor
10. Orexigen(R) Therapeutics Names Michael Narachi, 24-Year Biopharmaceutical Veteran, New President and Chief Executive Officer
11. HealthWorldWeb Adds Michael Millenson and J.D. Kleinke to Board of Advisors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2016)... ... May 28, 2016 , ... May 26, 2016- In ... Arts Fighting Challenge with theme event of “K Warriors” on June 4, 2016 at ... , The event is sponsored and hosted by Shaolin Institute and sanctioned by ...
(Date:5/27/2016)... , ... May 27, 2016 , ... Two director-level employees ... YWCA Tribute to Women and Industry (TWIN) 2016 honorees. The award recognizes businesswomen ... For this year, Geri Boone, Director of the MLTSS (Managed Long-Term Services and Supports) ...
(Date:5/27/2016)... NY (PRWEB) , ... May 27, 2016 , ... ... casual readers, this installment is bolstered by inspiring human-interest stories, courtesy of awareness-driven ... tech within the industry, from leading advocates, associations and industry leaders such as ...
(Date:5/27/2016)... ... May 27, 2016 , ... ... students studying complementary medicine. Allison Outerbridge is this year’s Life University ... May 18 at the university’s Student Leadership Awards ceremony. , Outerbridge is approaching ...
(Date:5/26/2016)... ... May 26, 2016 , ... Cabot Corporation, Pfizer, ... respirators, according to court documents and SEC filings. A jury has returned ... v. American Optical Corporation, Case No. BC588866, Los Angeles County, California. The jury ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... 27, 2016 Kitov ... focused on late-stage drug development, today announced the ... of pivotal batches required for registration of KIT-302 ... This follows Kitov,s announcement in December ... met its primary efficacy endpoint. "We ...
(Date:5/26/2016)... 2016 TARE (Transarterial Radio-embolization) ... Savings and Overall Decreased Use of Hospital ... international specialist healthcare company, has today announced the ... Meeting of ISPOR (International Society for Pharmacoeconomics and ... (HCC) using yttrium-90 glass microspheres is associated with ...
(Date:5/25/2016)... HILDEN , Deutschland und GERMANTOWN, ... Zusammenarbeit mit Therawis bedient ... Entscheidungen bei Brustkrebs   QIAGEN N.V. ... QIA) gab heute bekannt, eine Lizenz- und Entwicklungsvereinbarung ... prädiktiver Assays für die Onkologie eingegangen zu sein. ...
Breaking Medicine Technology: